Literature DB >> 17439322

A724A polymorphism of sarco(endo)plasmic reticulum Ca2+-ATPase 2 (SERCA2) in hypertensive patients.

Beata Kiec-Wilk1, Aldona Dembinska-Kiec, Agnieszka Olszanecka, Marek Bodzioch, Gerd Schmitz, Kalina Kawecka-Jaszcz.   

Abstract

BACKGROUND: Impaired function of calcium ion transporter sarco(endo)plasmic reticulum Ca2+-ATPase2 (SERCA2), encoded by ATP2A2 gene, was observed in hypertension. The aim of this study was to screen for mutations in the ATP2A2 gene, in hypertensive patients compared to healthy controls.
METHODS: The frequency of a novel mutation in exon 15 of ATP2A2, coding SERCA2, was studied in 107 hypertensive patients and a control group of 50 healthy volunteers. 24-h ambulatory blood-pressure monitoring (ABPM) was carried out. ATP2A2 genotyping was performed by denaturing HPLC and sequencing.
RESULTS: In exon 15 of the ATP2A2 gene, a novel c.2171G>A polymorphism was identified that does not change the amino acid sequence. The frequency of the A allele was significantly higher in normotensive controls than in hypertensive patients (p=0.017). GA genotype carriers demonstrated a tendency towards lower blood pressure values in the doctor's office (p=0.367 systolic, p=0.439 diastolic blood pressure) and measured by ABPM.
CONCLUSIONS: Our results suggest a protective role of the A724A (c.2171G>A) polymorphism of ATP2A2 in subjects without hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439322     DOI: 10.1515/CCLM.2007.092

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  Inactivation of Cys674 in SERCA2 increases BP by inducing endoplasmic reticulum stress and soluble epoxide hydrolase.

Authors:  Gang Liu; Fuhua Wu; Xiaoli Jiang; Yumei Que; Zhexue Qin; Pingping Hu; Kin Sing Stephen Lee; Jian Yang; Chunyu Zeng; Bruce D Hammock; Xiaoyong Tong
Journal:  Br J Pharmacol       Date:  2020-01-30       Impact factor: 8.739

2.  Novel mutations in Darier disease and association to self-reported disease severity.

Authors:  Ivone U S Leong; Alexander Stuckey; Tara Ahanian; Martin Cederlöf; Jakob D Wikstrom
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.